Table 2 |.
Guidelines for HbA1c targets in non-pregnant adults
| Organization | HbA1c target (%) | Qualifications | Ref. | |
|---|---|---|---|---|
| For most patients | For patients with shortened life expectancy or severe hypoglycaemia | |||
| ADA and EASD | <7 | <8 | GLP1 receptor agonist and/or SGLT2 inhibitor should be considered independently of HbA1c target in certain patient populations (C/AD, HF, CKD) | 36 |
| AACE–ACE | <6.5 | 7–8 | – | 37 |
| ACP | 7–8 | Avoid setting target | Consider de-escalation of therapy if HbA1c <6.5% | 38 |
| NICE | <6.5, <7 on hypoglycaemic drugs | Relax target | – | 39 |
| VA/DoD | 6–7 | 8–9 | Recommend taking patient characteristics (e.g. race, ethnicity, CKD and laboratory issues) into account when interpreting HbA1c | 40 |
| ICSI | <7 to <8 | <8 | – | 41 |
| SIGN | <7 | – | Target of <6.5% at diagnosis may be appropriate | 42 |
AACE, American Association of Clinical Endocrinologists; ACE, American College of Endocrinology; ACP, American College of Physicians; ADA, American Diabetes Association; CAD, coronary artery disease; CKD, chronic kidney disease; EASD, European Association for the Study of Diabetes; HbA1c, glycated haemoglobin A1c; HF, heart failure; ICSI, Institute for Clinical Systems Improvement; NICE, National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network; VA/DoD, US Department of Veterans Affairs and Department of Defense.